Drug Trial Radar · NCT07005713
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple-Ascending Doses of Tacabrutideg (BGB-16673) in Adults With Chronic Spontaneous Urticaria and in Healthy Participants
Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
58
Planned (sponsor's estimate)
Start
Jul 19, 2025
Primary completion
Nov 30, 2026
Study completion Nov 30, 2026
Sponsor
- Lead sponsor
- BeOne MedicinesBeOne Medicines (BeiGene) (ONC)
- Sponsor type
- Industry
- First posted
- Jun 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a Phase 1b study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of multiple-ascending doses of tacabrutideg in adults with chronic spontaneous urticaria (CSU) and in healthy participants.
Conditions
- Chronic Spontaneous Urticaria
Interventions
TacabrutidegDrug
Administered orally
PlaceboDrug
Administered orally
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part A: Number of participants with adverse events (AEs)Time frame: Up to approximately 4 months
- Part B: Number of participants with adverse events (AEs)Time frame: Up to approximately 6 weeks
- Part A: Maximum observed plasma concentration (Cmax) of tacabrutidegTime frame: Up to approximately 10 weeks
- Part A: Minimum observed plasma concentration (Cmin) of tacabrutidegTime frame: Up to approximately 10 weeks
- Part A: Time to reach maximum observed plasma concentration (Tmax) of tacabrutidegTime frame: Up to approximately 10 weeks
- Part A: Apparent terminal elimination half life (t1/2) of tacabrutidegTime frame: Up to approximately 10 weeks
- Part A: Area under the curve (AUC) of tacabrutidegTime frame: Up to approximately 10 weeks
- Part A: Apparent oral clearance (CL/F) of tacabrutidegTime frame: Up to approximately 10 weeks
- Part A: Apparent volume of distribution (Vz/F) of tacabrutidegTime frame: Up to approximately 10 weeks
- Part A: Accumulation Ratio of AUC for tacabrutidegTime frame: Up to approximately 10 weeks
- Part A: Accumulation Ratio of Cmax for tacabrutidegTime frame: Up to approximately 10 weeks
Locations
9 sites in 1 country. Site status is shown where the registry gives one.
Peking University Third Hospital
Beijing, Beijing Municipality, China · Completed
The First Affiliated Hospital of Chongqing Medical University
Chongqing, Chongqing Municipality, China · Completed
Dermatology Hospital of Southern Medical University
Guangzhou, Guangdong, China · Completed
Union Hospital of Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China · Completed
Xiangya Hospital of Central South University
Changsha, Hunan, China · Completed
The Affiliated Hospital of Qingdao University Branch West Coast
Qingdao, Shandong, China · Recruiting
Chengdu Second Peoples Hospital
Chengdu, Sichuan, China · Completed
Hangzhou First Peoples Hospital
Hangzhou, Zhejiang, China · Completed
The First Affiliated Hospital of Wenzhou Medical University
Wenzhou, Zhejiang, China · Completed
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.